Christopher T Sibley1, Tyra Estwick1, Anna Zavodni1, Chiung-Yu Huang1, Alan C Kwan1, Benjamin P Soule1, Debra A Long Priel1, Alan T Remaley1, Amanda K Rudman Spergel1, Evrim B Turkbey1, Douglas B Kuhns1, Steven M Holland1, Harry L Malech1, Kol A Zarember1, David A Bluemke1, John I Gallin2. 1. From the Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Center (C.T.S., A.Z., A.C.K., E.B.T., D.A.B.), Laboratory of Host Defenses (T.E., P.B.S., A.K.R.S., H.L.M., K.A.Z., J.I.G.), Biostatistics Research Branch (C.-Y.H.), and Laboratory of Clinical Infectious Diseases (S.M.H.), National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute (A.T.R.), National Institutes of Health, Bethesda, MD. 2. From the Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Center (C.T.S., A.Z., A.C.K., E.B.T., D.A.B.), Laboratory of Host Defenses (T.E., P.B.S., A.K.R.S., H.L.M., K.A.Z., J.I.G.), Biostatistics Research Branch (C.-Y.H.), and Laboratory of Clinical Infectious Diseases (S.M.H.), National Institute of Allergy and Infectious Diseases and National Heart, Lung, and Blood Institute (A.T.R.), National Institutes of Health, Bethesda, MD. jgallin@cc.nih.gov.
Abstract
BACKGROUND: Patients with chronic granulomatous disease (CGD) experience immunodeficiency because of defects in the phagocyte NADPH oxidase and the concomitant reduction in reactive oxygen intermediates. This may result in a reduction in atherosclerotic injury. METHODS AND RESULTS: We prospectively assessed the prevalence of cardiovascular risk factors, biomarkers of inflammation and neutrophil activation, and the presence of magnetic resonance imaging and computed tomography quantified subclinical atherosclerosis in the carotid and coronary arteries of 41 patients with CGD and 25 healthy controls in the same age range. Univariable and multivariable associations among risk factors, inflammatory markers, and atherosclerosis burden were assessed. Patients with CGD had significant elevations in traditional risk factors and inflammatory markers compared with control subjects, including hypertension, high-sensitivity C-reactive protein, oxidized low-density lipoprotein, and low high-density lipoprotein. Despite this, patients with CGD had a 22% lower internal carotid artery wall volume compared with control subjects (361.3±76.4 mm(3) versus 463.5±104.7 mm(3); P<0.001). This difference was comparable in p47(phox)- and gp91(phox)-deficient subtypes of CGD and independent of risk factors in multivariate regression analysis. In contrast, the prevalence of coronary arterial calcification was similar between patients with CGD and control subjects (14.6%, CGD; 6.3%, controls; P=0.39). CONCLUSIONS: The observation by magnetic resonance imaging and computerized tomography of reduced carotid but not coronary artery atherosclerosis in patients with CGD despite the high prevalence of traditional risk factors raises questions about the role of NADPH oxidase in the pathogenesis of clinically significant atherosclerosis. Additional high-resolution studies in multiple vascular beds are required to address the therapeutic potential of NADPH oxidase inhibition in cardiovascular diseases. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01063309.
BACKGROUND:Patients with chronic granulomatous disease (CGD) experience immunodeficiency because of defects in the phagocyte NADPH oxidase and the concomitant reduction in reactive oxygen intermediates. This may result in a reduction in atherosclerotic injury. METHODS AND RESULTS: We prospectively assessed the prevalence of cardiovascular risk factors, biomarkers of inflammation and neutrophil activation, and the presence of magnetic resonance imaging and computed tomography quantified subclinical atherosclerosis in the carotid and coronary arteries of 41 patients with CGD and 25 healthy controls in the same age range. Univariable and multivariable associations among risk factors, inflammatory markers, and atherosclerosis burden were assessed. Patients with CGD had significant elevations in traditional risk factors and inflammatory markers compared with control subjects, including hypertension, high-sensitivity C-reactive protein, oxidized low-density lipoprotein, and low high-density lipoprotein. Despite this, patients with CGD had a 22% lower internal carotid artery wall volume compared with control subjects (361.3±76.4 mm(3) versus 463.5±104.7 mm(3); P<0.001). This difference was comparable in p47(phox)- and gp91(phox)-deficient subtypes of CGD and independent of risk factors in multivariate regression analysis. In contrast, the prevalence of coronary arterial calcification was similar between patients with CGD and control subjects (14.6%, CGD; 6.3%, controls; P=0.39). CONCLUSIONS: The observation by magnetic resonance imaging and computerized tomography of reduced carotid but not coronary artery atherosclerosis in patients with CGD despite the high prevalence of traditional risk factors raises questions about the role of NADPH oxidase in the pathogenesis of clinically significant atherosclerosis. Additional high-resolution studies in multiple vascular beds are required to address the therapeutic potential of NADPH oxidase inhibition in cardiovascular diseases. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01063309.
Authors: P A Barry-Lane; C Patterson; M van der Merwe; Z Hu; S M Holland; E T Yeh; M S Runge Journal: J Clin Invest Date: 2001-11 Impact factor: 14.808
Authors: Dan Sorescu; Daiana Weiss; Bernard Lassègue; Roza E Clempus; Katalin Szöcs; George P Sorescu; Liisa Valppu; Mark T Quinn; J David Lambeth; J David Vega; W Robert Taylor; Kathy K Griendling Journal: Circulation Date: 2002-03-26 Impact factor: 29.690
Authors: A Schmermund; R S Schwartz; M Adamzik; G Sangiorgi; E A Pfeifer; J A Rumberger; A P Burke; A Farb; R Virmani Journal: Atherosclerosis Date: 2001-04 Impact factor: 5.162
Authors: J A Winkelstein; M C Marino; R B Johnston; J Boyle; J Curnutte; J I Gallin; H L Malech; S M Holland; H Ochs; P Quie; R H Buckley; C B Foster; S J Chanock; H Dickler Journal: Medicine (Baltimore) Date: 2000-05 Impact factor: 1.889
Authors: E Hsich; B H Segal; P J Pagano; F E Rey; B Paigen; J Deleonardis; R F Hoyt; S M Holland; T Finkel Journal: Circulation Date: 2000-03-21 Impact factor: 29.690
Authors: Christopher T Sibley; Andrea L Vavere; Ilan Gottlieb; Christopher Cox; Matthew Matheson; Amy Spooner; Gustavo Godoy; Veronica Fernandes; Bruce A Wasserman; David A Bluemke; Joao A C Lima Journal: Heart Date: 2013-07-19 Impact factor: 5.994
Authors: I M Quesada; A Lucero; C Amaya; D N Meijles; M E Cifuentes; P J Pagano; C Castro Journal: Atherosclerosis Date: 2015-08-08 Impact factor: 5.162
Authors: John Audley; Emily F Gliniewicz; Kol A Zarember; Hanna S Hong; Gal Wald; Douglas B Kuhns; Elizabeth Kang; Harry L Malech; Anthony F Suffredini; Robert J Noveck; Mark J Dinubile; Susan L Levinson; Thomas P Stossel; John I Gallin Journal: Inflammation Date: 2020-09-04 Impact factor: 4.092
Authors: Jose Luis Martin-Ventura; Raquel Rodrigues-Diez; Diego Martinez-Lopez; Mercedes Salaices; Luis Miguel Blanco-Colio; Ana M Briones Journal: Int J Mol Sci Date: 2017-11-03 Impact factor: 5.923
Authors: Christoph Schürmann; Flavia Rezende; Christoph Kruse; Yakub Yasar; Oliver Löwe; Christian Fork; Bart van de Sluis; Rolf Bremer; Norbert Weissmann; Ajay M Shah; Hanjoong Jo; Ralf P Brandes; Katrin Schröder Journal: Eur Heart J Date: 2015-09-17 Impact factor: 29.983
Authors: Christian Lood; Luz P Blanco; Monica M Purmalek; Carmelo Carmona-Rivera; Suk S De Ravin; Carolyne K Smith; Harry L Malech; Jeffrey A Ledbetter; Keith B Elkon; Mariana J Kaplan Journal: Nat Med Date: 2016-01-18 Impact factor: 53.440